Top

Published in:

01-05-2023 | Nitrofurantoin | News item

Nitrofurantoin-related risks of pulmonary and hepatic ADRs

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Healthcare professionals prescribing nitrofurantoin should be aware of the risks of pulmonary and hepatic adverse drug reactions (ADRs) and advise patients to be aware of lung and liver signs and symptoms that require investigation, says the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Drug Safety Update . …

Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions Drug Safety Update : 26 Apr 2023. Available from: URL: https://www.gov.uk/drug-safety-update/nitrofurantoin-reminder-of-the-risks-of-pulmonary-and-hepatic-adverse-drug-reactions

Title: Nitrofurantoin-related risks of pulmonary and hepatic ADRs
Publication date: 01-05-2023
Publisher: Springer International Publishing
Keywords: Nitrofurantoin
Hepatitis
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-38252-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Nitrofurantoin-related risks of pulmonary and hepatic ADRs

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Pembrolizumab

Aripiprazole

Sucralfate/unspecified proton pump inhibitors

Diclofenac

Multiple drugs

Multiple drugs